 |
 |  |
        |
 Press Release: January 7, 2008 Tampa, FL - Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer. Most recently, Dr. Keeffe served as Professor of Medicine, Chief of Hepatology and Co-Director of the Liver Transplant Program at Stanford University Medical Center. He is a past-president of the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, and served as chair of the Subspecialty Board on Gastroenterology for the American Board of Internal Medicine. He is a Master of the American College of Physicians and a Fellow of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American College of Gastroenterology, and the Royal College of Physicians of Ireland. "Romark's drug discovery research and ongoing clinical development programs offer the promise of new drugs that could change paradigms for treating viral hepatitis," said Dr. Keeffe. "I am excited to have the opportunity to contribute to the advancement of new therapies in this field." Dr. Keeffe's research interests include antiviral therapy of chronic hepatitis B and C, use of hepatitis vaccines, and liver transplant selection criteria and outcomes. Throughout his career, he has been an active clinical investigator, with a major focus on novel treatment of chronic viral hepatitis and has published more than 500 papers, book chapters and miscellaneous publications. He lectures widely at national and international scientific meetings, and postgraduate courses. "We are pleased that Dr. Keeffe has chosen to join our Company, said Jean-François Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "His expertise in the fields of hepatology and gastroenterology will be invaluable as we advance the development of nitazoxanide and other thiazolides for treating viral hepatitis and other digestive diseases. About Romark Laboratories Romark Laboratories, L.C. (www.romark.com) is a biotechnology company committed to the discovery and development of innovative new small molecules for treating infectious diseases, cancers, and autoimmune diseases. The Company is developing nitazoxanide for treating chronic hepatitis C and is developing other new thiazolides for treating viral diseases including chronic hepatitis B and C, and influenza. << see more |
 |
 |
||